• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫细胞在肝癌中抗原呈递和 T 细胞反应调控中的复杂作用:进展、挑战和未来方向。

The complex role of immune cells in antigen presentation and regulation of T-cell responses in hepatocellular carcinoma: progress, challenges, and future directions.

机构信息

The Fourth Clinical College, China Medical University, Shenyang, China.

Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Front Immunol. 2024 Oct 22;15:1483834. doi: 10.3389/fimmu.2024.1483834. eCollection 2024.

DOI:10.3389/fimmu.2024.1483834
PMID:39502703
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11534672/
Abstract

Hepatocellular carcinoma (HCC) is a prevalent form of liver cancer that poses significant challenges regarding morbidity and mortality rates. In the context of HCC, immune cells play a vital role, especially concerning the presentation of antigens. This review explores the intricate interactions among immune cells within HCC, focusing on their functions in antigen presentation and the modulation of T-cell responses. We begin by summarizing the strategies that HCC uses to escape immune recognition, emphasizing the delicate equilibrium between immune surveillance and evasion. Next, we investigate the specific functions of various types of immune cells, including dendritic cells, natural killer (NK) cells, and CD8+ T cells, in the process of antigen presentation. We also examine the impact of immune checkpoints, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the pathways involving programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1), on antigen presentation, while taking into account the clinical significance of checkpoint inhibitors. The review further emphasizes the importance of immune-based therapies, including cancer vaccines and CAR-T cell therapy, in improving antigen presentation. In conclusion, we encapsulate the latest advancements in research, propose future avenues for exploration, and stress the importance of innovative technologies and customized treatment strategies. By thoroughly analyzing the interactions of immune cells throughout the antigen presentation process in HCC, this review provides an up-to-date perspective on the field, setting the stage for new therapeutic approaches.

摘要

肝细胞癌(HCC)是一种常见的肝癌形式,其发病率和死亡率都很高。在 HCC 中,免疫细胞起着至关重要的作用,尤其是在抗原呈递方面。这篇综述探讨了 HCC 中免疫细胞之间复杂的相互作用,重点关注它们在抗原呈递和 T 细胞反应调节中的功能。我们首先总结了 HCC 逃避免疫识别的策略,强调了免疫监视和逃逸之间的微妙平衡。接下来,我们研究了各种类型的免疫细胞,包括树突状细胞、自然杀伤(NK)细胞和 CD8+T 细胞,在抗原呈递过程中的特定功能。我们还研究了免疫检查点(如细胞毒性 T 淋巴细胞相关蛋白 4(CTLA-4)以及涉及程序性细胞死亡蛋白 1(PD-1)和程序性死亡配体 1(PD-L1)的途径)对抗原呈递的影响,同时考虑了检查点抑制剂的临床意义。该综述进一步强调了免疫为基础的治疗方法(包括癌症疫苗和嵌合抗原受体 T 细胞疗法)在改善抗原呈递方面的重要性。总之,我们总结了最新的研究进展,提出了未来的探索方向,并强调了创新技术和定制治疗策略的重要性。通过深入分析 HCC 中免疫细胞在抗原呈递过程中的相互作用,本综述为该领域提供了最新的视角,为新的治疗方法奠定了基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a84/11534672/b0cbff93c8a5/fimmu-15-1483834-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a84/11534672/ae398ac1a0cd/fimmu-15-1483834-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a84/11534672/8bf741224f14/fimmu-15-1483834-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a84/11534672/b0cbff93c8a5/fimmu-15-1483834-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a84/11534672/ae398ac1a0cd/fimmu-15-1483834-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a84/11534672/8bf741224f14/fimmu-15-1483834-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a84/11534672/b0cbff93c8a5/fimmu-15-1483834-g003.jpg

相似文献

1
The complex role of immune cells in antigen presentation and regulation of T-cell responses in hepatocellular carcinoma: progress, challenges, and future directions.免疫细胞在肝癌中抗原呈递和 T 细胞反应调控中的复杂作用:进展、挑战和未来方向。
Front Immunol. 2024 Oct 22;15:1483834. doi: 10.3389/fimmu.2024.1483834. eCollection 2024.
2
Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.提高免疫疗法治疗肝细胞癌抗肿瘤效果的策略。
Front Immunol. 2021 Nov 26;12:783236. doi: 10.3389/fimmu.2021.783236. eCollection 2021.
3
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.针对免疫检查点分子的抗体恢复了肝癌浸润 T 细胞的功能。
Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23.
4
The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review.主要免疫效应细胞与肝细胞癌的相互作用:系统评价。
Int Immunopharmacol. 2021 Dec;101(Pt A):108220. doi: 10.1016/j.intimp.2021.108220. Epub 2021 Oct 18.
5
Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.抗 PD-1/PD-L1 阻断免疫疗法治疗乙型肝炎病毒感染相关的晚期肝细胞癌:文献综述。
Front Immunol. 2020 May 28;11:1037. doi: 10.3389/fimmu.2020.01037. eCollection 2020.
6
Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches.自然杀伤细胞和 T 细胞在肝细胞癌和病毒性肝炎中的作用:当前现状及未来免疫治疗方法的展望。
Cells. 2021 May 28;10(6):1332. doi: 10.3390/cells10061332.
7
Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.肿瘤相关巨噬细胞中程序性死亡配体 1 蛋白的优先表达及其在肝癌免疫治疗中的潜在作用。
Int J Mol Sci. 2021 Apr 29;22(9):4710. doi: 10.3390/ijms22094710.
8
Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.免疫疗法作为治疗肝细胞癌的新方法的出现。
World J Gastroenterol. 2018 May 7;24(17):1839-1858. doi: 10.3748/wjg.v24.i17.1839.
9
Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.基于生物纳米颗粒的疫苗和检查点阻断刺激的适应性抗肿瘤免疫反应。
J Exp Clin Cancer Res. 2022 Apr 8;41(1):132. doi: 10.1186/s13046-022-02307-3.
10
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.肝癌肿瘤免疫微环境与免疫抑制治疗:综述。
Int J Mol Sci. 2021 May 28;22(11):5801. doi: 10.3390/ijms22115801.

引用本文的文献

1
Clinical trials of nanoparticle-enhanced CAR-T and NK cell therapies in oncology: overcoming translational and clinical challenges - a mini review.纳米颗粒增强型CAR-T和NK细胞疗法在肿瘤学中的临床试验:克服转化和临床挑战——一篇综述
Front Med (Lausanne). 2025 Aug 6;12:1655693. doi: 10.3389/fmed.2025.1655693. eCollection 2025.
2
Immunomodulatory Effects of LSI312A on Dendritic Cells: A Novel Approach to Modulating Inflammatory Pathways.LSI312A对树突状细胞的免疫调节作用:调节炎症通路的新方法。
J Microbiol Biotechnol. 2025 Aug 18;35:e2506027. doi: 10.4014/jmb.2506.06027.
3
Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends.

本文引用的文献

1
Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response.全面泛癌分析揭示 EphB2 是一种新的预测预后和免疫治疗反应的生物标志物。
BMC Cancer. 2024 Aug 28;24(1):1064. doi: 10.1186/s12885-024-12843-0.
2
Nanomaterials in crossroad of autophagy control in human cancers: Amplification of cell death mechanisms.纳米材料在人类癌症自噬调控的十字路口:细胞死亡机制的放大。
Cancer Lett. 2024 Jun 1;591:216860. doi: 10.1016/j.canlet.2024.216860. Epub 2024 Apr 6.
3
Intratumoral dendritic cell-CD4 T helper cell niches enable CD8 T cell differentiation following PD-1 blockade in hepatocellular carcinoma.
肝细胞癌中PD-1/PD-L1免疫治疗的结构与时间动态分析:历史、研究热点及新趋势
Hum Vaccin Immunother. 2025 Dec;21(1):2540143. doi: 10.1080/21645515.2025.2540143. Epub 2025 Aug 17.
4
Changing landscape of advanced esophageal squamous cell carcinoma: Breakthroughs in systemic therapies (Review).晚期食管鳞状细胞癌的变化格局:全身治疗的突破(综述)
Oncol Rep. 2025 Oct;54(4). doi: 10.3892/or.2025.8953. Epub 2025 Jul 19.
5
Machine learning assists regulated cell death crucial biomarker selection in adenocarcinoma of the lung: biological data testing and cell assay determination.机器学习助力肺癌腺癌中调节性细胞死亡关键生物标志物的选择:生物学数据测试与细胞试验测定
Discov Oncol. 2025 Jul 8;16(1):1285. doi: 10.1007/s12672-025-02793-9.
6
Overcoming barriers in glioblastoma: The potential of CAR T cell immunotherapy.克服胶质母细胞瘤中的障碍:嵌合抗原受体T细胞免疫疗法的潜力。
Theranostics. 2025 Jun 12;15(14):7090-7126. doi: 10.7150/thno.114257. eCollection 2025.
7
Integrating inflammation, nutrition, and immunity: the CALLY index as a prognostic tool in digestive system cancers - a systematic review and meta-analysis.整合炎症、营养与免疫:CALLY指数作为消化系统癌症预后工具的系统评价与荟萃分析
BMC Cancer. 2025 Apr 11;25(1):672. doi: 10.1186/s12885-025-14074-3.
8
Construction and evaluation of a prognostic model of autophagy-related genes in hepatocellular carcinoma.肝细胞癌自噬相关基因预后模型的构建与评估
Biochem Biophys Rep. 2024 Dec 12;41:101893. doi: 10.1016/j.bbrep.2024.101893. eCollection 2025 Mar.
肿瘤内树突状细胞-CD4+T 辅助细胞龛促进 PD-1 阻断后肝癌中 CD8+T 细胞的分化。
Nat Med. 2023 Jun;29(6):1389-1399. doi: 10.1038/s41591-023-02345-0. Epub 2023 Jun 15.
4
Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.肿瘤相关巨噬细胞和 PD-L1 在肝癌患者中的表达及预后模型的构建。
J Cancer Res Clin Oncol. 2023 Sep;149(12):10685-10700. doi: 10.1007/s00432-023-04949-y. Epub 2023 Jun 12.
5
MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors.MHC Ⅱ类限制的抗原呈递对于防止血源性髓样细胞在脑肿瘤中引起细胞毒性 T 细胞功能障碍是必需的。
Cancer Cell. 2023 Feb 13;41(2):235-251.e9. doi: 10.1016/j.ccell.2022.12.007. Epub 2023 Jan 12.
6
γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.γδ T 细胞是 HLA I 类缺陷癌症免疫治疗的效应细胞。
Nature. 2023 Jan;613(7945):743-750. doi: 10.1038/s41586-022-05593-1. Epub 2023 Jan 11.
7
PD-L1 is associated with the prognosis of penile cancer: A systematic review and meta-analysis.程序性死亡受体配体1(PD-L1)与阴茎癌预后相关:一项系统评价和荟萃分析。
Front Oncol. 2022 Nov 30;12:1013806. doi: 10.3389/fonc.2022.1013806. eCollection 2022.
8
PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells.PRDM1/BLIMP1 通过调节肝癌细胞中的 USP22-SPI1-PD-L1 轴诱导癌症免疫逃逸。
Nat Commun. 2022 Dec 12;13(1):7677. doi: 10.1038/s41467-022-35469-x.
9
Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients.亚型特异性PD-1介导的免疫抑制是肝细胞癌患者对PD-1阻断治疗产生耐药性的基础。
Gut. 2023 Aug;72(8):1568-1580. doi: 10.1136/gutjnl-2022-327133. Epub 2022 Nov 30.
10
NR4A1 mediates NK-cell dysfunction in hepatocellular carcinoma via the IFN-γ/p-STAT1/IRF1 pathway.NR4A1 通过 IFN-γ/p-STAT1/IRF1 通路介导肝癌中 NK 细胞功能障碍。
Immunology. 2023 May;169(1):69-82. doi: 10.1111/imm.13611. Epub 2022 Dec 1.